Recent Updates
Recently added Catalysts
RXRX Positive Sentiment

Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th

Wednesday, July 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Recursion, a clinical stage TechBio company, is scheduled to host a public earnings call on August 5th, 2026, at 8:00 am ET. During this call, the company will provide updates on its business and financial results. This engagement reflects Recursion's commitment to transparency with its stakeholders.
Price reaction · baseline $3.05 (2026-07-28 close) · hit pre-market · clean, no other RXRX news in the window
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Recursion is actively engaging with the public through an earnings call.
  • The company is set to report its business updates and financial results.
  • The scheduled call indicates transparency and communication with stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
3.8%
average across 3 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
REC-994
Phase 2 · Cerebral Cavernous Malformation

Full Press Release Details

Company to host public Earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) -- Salt Lake City, UT, July 29, 2026 (GLOBE NEWSWIRE) – Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically

Frequently Asked Questions

When is Recursion's earnings call scheduled?

Recursion's earnings call is scheduled for August 5th, 2026.

What time will the earnings call take place?

The earnings call will occur at 8:00 am ET.

What will Recursion discuss during the call?

Recursion will discuss its business updates and financial results.

Where is Recursion based?

Recursion is based in Salt Lake City, UT.

ShareAdd on Google
Tags: RXRX Viatris Investor Conferences Healthcare Recursion earnings call financial results business updates
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$546M liquidity · $35M/mo burn
~15 mo
Low dilution risk
Lead asset
REC-994Phase 2
Cerebral Cavernous Malformation →

Catalyst track record

+65%
best trade around RXRX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for RXRX.

See every catalyst's timing & PoA →